Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up
Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up
复制标题
DOI：
10.1177/000348940511400608
复制
发表时间：
2005-06-01
影响因子：
1.4
通讯作者：
Pfister, H
中科院分区：
文献类型：
--
作者：
Gerein, V;Rastorguev, E;Pfister, H
Objectives: The aim of this study was analysis of the results of use of interferon-alpha (IFN-alpha) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type.Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-a in doses of 3 MU/m(2) 3 times per week.Results: During long-term follow-up (mean SD, 172 +/- 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease course (64% of HPV I I patients versus 24% of HPV 6 patients), a lower incidence of long-term response to IFN-alpha therapy (14% of HPV 11 patients versus 64% of HPV 6 patients), and a higher incidence of malignant transformation and mortality during follow-up (36% and 24%, respectively, of HPV I I patients versus 0% of HPV 6 patients).Conclusions: The obtained results revealed maximal effectiveness of IFN-alpha therapy in RRP patients with HPV 6 as compared with HPV 11. The association of HPV I I with a worse long-term response to IFN-alpha therapy and a higher incidence of malignant transformation and mortality is clinically important and indicates the necessity of HPV typing in RRP patients after the first biopsy.
